The October settlement update means most federal Depo-Provera claims now have a settlement path, but no public payment amounts or payout schedule. Depo-Provera, the injectable medroxyprogesterone acetate contraceptive, is at the center of federal meningioma litigation centralized as MDL No.
3140. Pfizer and plaintiffs' leadership announced a global agreement in principle on June 15, 2026, then signed a confidential Master Settlement Agreement on July 21, 2026. Miller & Zois reports the agreement covers a majority of MDL claims in the October settlement summary.
Official resources:
- Read the official notice from Lawsuit Information Center — Use this primary source to verify the official announcement.
- Read the original report from News Medical — Use this primary source to review the complete report.
Table of Contents
- How large is the litigation?
- Who may qualify for settlement?
- What is still confidential?
- When could payments arrive?
- What evidence supports the claims?
- What if you do not settle?
- Frequently Asked Questions
How large is the litigation?
The Judicial Panel on Multidistrict Litigation centralized federal Depo-Provera meningioma cases before Judge M. Casey Rodgers in the Northern District of Florida on February 7, 2025. Centralization places related pretrial proceedings before one judge for efficiency.
The docket continued to grow after the preliminary settlement. According to AboutLawsuits, the federal MDL reached 6,412 pending lawsuits as of October 1, 2026 in the federal docket update. Readers should track MDL status, not state-court filings alone, when judging momentum.
Who may qualify for settlement?
The parties estimate roughly 80% of current federal MDL plaintiffs will be eligible to participate. Eligibility centers principally on women with Depo-Provera injections followed by intracranial meningioma diagnosis.
Use this check before calling a firm: Final eligibility turns on the confidential proof rules. A lawyer can compare injection history and pathology or imaging records against those rules.
- Depo-Provera injections, not another birth-control method
- Later diagnosis of intracranial meningioma
- Medical and pharmacy records linking injections and diagnosis
- Claim already filed or promptly reviewed for filing deadlines
What is still confidential?
Settlement tiers, medical-proof requirements, individual payment amounts, and registration terms remain confidential. There is no public payout schedule.
Terms are expected to be disclosed through a court town hall, not through a posted settlement grid. That means readers cannot yet calculate likely compensation from surgery history or tumor severity.
When could payments arrive?
Registration is expected to finish in November 2026. Claims processing and first payments are projected for the first quarter of 2027.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
That timeline assumes records review moves without delay. Missing pharmacy files, incomplete imaging reports, or pathology gaps can slow an individual claim.
What evidence supports the claims?
A March 2024 French national case-control study in The BMJ linked longer injectable medroxyprogesterone acetate use to higher odds of surgically treated intracranial meningioma. Use for over one year was associated with about 5.6-fold higher odds.
The FDA then approved a December 2025 Depo-Provera label change adding a meningioma warning. According to DrugWatch, the warning directs doctors to monitor users and stop the drug if meningioma is diagnosed in the label-change summary. The label does not decide individual causation.
What if you do not settle?
Women who do not qualify or reject settlement can keep litigating. Continued litigation means facing contested causation and filing-deadline fights.
The court has a general-causation and Rule 702 hearing set for September 18, 2026, alongside expedited statute-of-limitations rulings. Unfiled claims should not assume deadlines are paused during settlement registration.
Frequently Asked Questions
Do I need surgery to qualify?
The public summary describes eligibility around Depo-Provera injections followed by intracranial meningioma diagnosis, but surgical and proof requirements remain confidential.
Are settlement amounts public?
No. Tiers, proof rules, individual amounts, and registration terms have not been publicly disclosed.
Should I wait to file because settlement was announced?
No. Litigation continues for non-settling claims, with causation and limitations rulings ahead, so get filing deadlines checked promptly.
You Might Also Like
- Monsanto Roundup Lawsuit Settlement Payout Update for October 2026
- Spinal Cord Stimulator Lawsuit: October 2026 Eligibility Update
- Depo Provera Lawsuit Settlement Update: What October 2026 Changed